Next 10 |
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
NeuroMetrix, Inc. (NASDAQ: NURO) is one of today's top gainers. The company's shares have moved 18.2% on the day to $4.3. NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeu...
2024-04-19 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
2024-04-19 09:10:08 ET More on NeuroMetrix NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript Financial information for NeuroMetrix Read the full article on Seeking Alpha For further details see: NeuroMetrix names new independent director, terminat...
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its l...
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck ® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleag...
WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. “We have been pleased by the positive response to Quel...
NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently personally paid the FTC $4 million as part of a settlement Gozani barely owns any ...
- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's leadership - Sees no reason for company to remain public NEW YORK, NY / ACCESS...
2024-02-22 11:55:19 ET NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Conference Call February 24, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founder and Chief Executive Officer Conference Ca...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetri...
NeuroMetrix, Inc. (NASDAQ: NURO) is one of today's top gainers. The company's shares have moved 18.2% on the day to $4.3. NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeu...